Grondin R, Goulet M, Di Paolo T, Bédard P J
Department of Pharmacology, Faculty of Medicine, Laval University, Quebec, Canada.
Brain Res. 1996 Oct 7;735(2):298-306. doi: 10.1016/0006-8993(96)00597-5.
Continuous dopaminergic receptor stimulation is now considered as an interesting approach for the control of motor complications often seen in parkinsonian patients treated chronically with levodopa. Cabergoline, which is a long-acting dopamine D2-like receptor agonist, has been tried recently with good results as an adjunct in patients already on levodopa-therapy. Thus, the present study was designed to test the effects of repeated s.c. administration of cabergoline as sole therapeutic agent during a month in 3 drug-naive MPTP parkinsonian monkeys to see whether or not cabergoline, given every other day at 0.25 mg/kg, would have a sustained antiparkinsonian effect and would induce dyskinesias. The animals were rated to quantify the antiparkinsonian as well as the dyskinetic response and gross locomotor activity was monitored by photocells. The averaged locomotor response, initially greatly increased (approximately 9 times higher than after saline treatment in the same animals), decreased by approximately 50% after 2 weeks but was thereafter maintained at this level until the end of the study. The parkinsonian features were improved in a sustained manner in all monkeys and transient dyskinesias (week 1 and 2) were present in 2 of 3 monkeys. After sacrifice receptor binding assays were performed on striatal and pallidal tissues homogenates with tritiated selective ligands and compared with those of 3 normal and 3 MPTP-exposed monkeys otherwise untreated. A significant decrease in dopamine D2-like receptor density in the putamen (-36% on average vs. untreated MPTP-exposed monkeys) may be involved in the behavioral partial tolerance to antiparkinsonian effect of cabergoline and the disappearance of dyskinesias. A reversal of the supersensitivity of GABAA receptor in the internal segment of the globus pallidus (-15% on average vs. untreated MPTP-exposed monkeys) may also be implicated in this latter behavioral effect.
持续的多巴胺能受体刺激现在被认为是一种有意义的方法,用于控制长期接受左旋多巴治疗的帕金森病患者中常见的运动并发症。卡麦角林是一种长效多巴胺D2样受体激动剂,最近已被尝试作为左旋多巴治疗患者的辅助药物,取得了良好的效果。因此,本研究旨在测试在3只未接受过药物治疗的MPTP诱导的帕金森病猴子中,连续皮下注射卡麦角林作为唯一治疗药物一个月的效果,以观察每隔一天给予0.25mg/kg的卡麦角林是否会产生持续的抗帕金森病作用并诱发运动障碍。对动物进行评分以量化抗帕金森病以及运动障碍反应,并通过光电管监测总体运动活动。平均运动反应最初大幅增加(比同一只动物接受生理盐水治疗后高约9倍),2周后下降约50%,但此后一直维持在该水平直至研究结束。所有猴子的帕金森病特征均得到持续改善,3只猴子中有2只出现了短暂的运动障碍(第1周和第2周)。处死动物后,用氚标记的选择性配体对纹状体和苍白球组织匀浆进行受体结合测定,并与3只正常猴子和3只未接受其他治疗的MPTP暴露猴子进行比较。壳核中多巴胺D2样受体密度显著降低(平均比未接受治疗的MPTP暴露猴子低36%)可能与对卡麦角林抗帕金森病作用的行为部分耐受性以及运动障碍的消失有关。苍白球内侧段GABAA受体超敏反应的逆转(平均比未接受治疗的MPTP暴露猴子低15%)也可能与后一种行为效应有关。